Empowered Patient Podcast Targeting and Deploying Optimum Radiopharmaceuticals to Treat Cancer with Jack Hoppin and John Babich Ratio Therapeutics
Jack Hoppin Ph.D. Chief Executive Officer and John Babich Ph.D., President and Chief Scientific Officer, and Co-Founders of Ratio Therapeutics aim to develop and produce best-in-class radiopharmaceuticals. Harnessing the power of radiation by making it into an injectable drug, Ratio is creating a way to find tumor cells anywhere in the body.
John explains, "And what we are doing, which is quite unique, is creating a platform of small molecules that can be radiolabeled with a variety of different isotopes. And these radioactive isotopes carry the ability to deliver different types of radiation -- beta particles and alpha particles. They have different toxicities and different lengths, so they travel in the tissue. And by combining the right molecules for the delivery with the right isotope, we're hoping to optimize the ability to control the tumor to basically put it into remission while maintaining a high quality of life. And we do that latter component by making sure that the injected material doesn't go to normal tissues and damage normal tissues."
"So we're trying to enhance the ratio of the delivery between the tumor itself and the normal tissues. The higher that ratio, the better off we are in being able to provide patients with a good treatment while maintaining a high quality of a life."
Jack elaborates, "That's the uniqueness of the platform in terms of the market itself. John was a pioneer in this market, and he has been in the space for some time. It's really been known in the past, and it's not a novel concept. Radioactive iodines have been used for a long time, and there's been a class of drugs, a few drugs adopted, but in the last five years or so, we've seen a big boom in the adoption of targeted radiotherapies."
@Ratio_Tx #Ratio #RatioTx #RatioTherapeutics #Radioactive #Radiopharmaceuticals #cancer #onco #MathMeetsMedicine #Pharmokinetics #Tumor